APPLIED DNA SCIENCES INC (APDN)
US03815U4094 - Common Stock
We assign a fundamental rating of 2 out of 10 to APDN. APDN was compared to 57 industry peers in the Life Sciences Tools & Services industry. While APDN seems to be doing ok healthwise, there are quite some concerns on its profitability. APDN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
APDN had negative earnings in the past year.
APDN had a negative operating cash flow in the past year.
In the past 5 years APDN always reported negative net income.
In the past 5 years APDN always reported negative operating cash flow.
1.2 Ratios
APDN has a worse Return On Assets (-56.50%) than 91.07% of its industry peers.
With a Return On Equity value of -79.03%, APDN is not doing good in the industry: 76.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.5% | ||
| ROE | -79.03% | ||
| ROIC | N/A |
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 29.64%, APDN is not doing good in the industry: 73.21% of the companies in the same industry are doing better.
APDN's Gross Margin has declined in the last couple of years.
APDN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
2. Health
2.1 Basic Checks
APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APDN has been increased compared to 1 year ago.
APDN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for APDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
APDN has an Altman-Z score of -35.23. This is a bad value and indicates that APDN is not financially healthy and even has some risk of bankruptcy.
APDN has a worse Altman-Z score (-35.23) than 98.21% of its industry peers.
There is no outstanding debt for APDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -35.23 |
ROIC/WACCN/A
WACC11.27%
2.3 Liquidity
A Current Ratio of 3.36 indicates that APDN has no problem at all paying its short term obligations.
APDN's Current ratio of 3.36 is in line compared to the rest of the industry. APDN outperforms 58.93% of its industry peers.
APDN has a Quick Ratio of 3.17. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.17, APDN is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.36 | ||
| Quick Ratio | 3.17 |
3. Growth
3.1 Past
APDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.60%, which is quite impressive.
The Revenue for APDN has decreased by -74.33% in the past year. This is quite bad
Measured over the past years, APDN shows a decrease in Revenue. The Revenue has been decreasing by -8.63% on average per year.
EPS 1Y (TTM)53.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.85%
Revenue 1Y (TTM)-74.33%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%3.85%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for APDN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APDN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for APDN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APPLIED DNA SCIENCES INC
NASDAQ:APDN (12/20/2024, 8:00:00 PM)
After market: 0.1778 +0 (+0.4%)0.1771
-0.01 (-5.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.86%
Inst Owner Change8.1%
Ins Owners0.95%
Ins Owner Change0%
Market Cap9.07M
Analysts43.33
Price Target1.53 (763.92%)
Short Float %3.54%
Short Ratio0.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)119.69%
Min EPS beat(2)7.73%
Max EPS beat(2)231.65%
EPS beat(4)3
Avg EPS beat(4)73.81%
Min EPS beat(4)-15.69%
Max EPS beat(4)231.65%
EPS beat(8)6
Avg EPS beat(8)53.23%
EPS beat(12)9
Avg EPS beat(12)40.58%
EPS beat(16)9
Avg EPS beat(16)19.02%
Revenue beat(2)0
Avg Revenue beat(2)-19.64%
Min Revenue beat(2)-27.61%
Max Revenue beat(2)-11.67%
Revenue beat(4)1
Avg Revenue beat(4)-7.71%
Min Revenue beat(4)-27.61%
Max Revenue beat(4)12.59%
Revenue beat(8)4
Avg Revenue beat(8)-5.34%
Revenue beat(12)7
Avg Revenue beat(12)-0.43%
Revenue beat(16)10
Avg Revenue beat(16)-0.31%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.99 | ||
| P/tB | 1.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.96
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.07
BVpS0.18
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.5% | ||
| ROE | -79.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.64% | ||
| FCFM | N/A |
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
F-Score3
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 58.57% | ||
| Cap/Sales | 11.89% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.36 | ||
| Quick Ratio | 3.17 | ||
| Altman-Z | -35.23 |
F-Score3
WACC11.27%
ROIC/WACCN/A
Cap/Depr(3y)60.08%
Cap/Depr(5y)170.88%
Cap/Sales(3y)7.71%
Cap/Sales(5y)21.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.85%
EPS Next Y84.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-74.33%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%3.85%
Revenue Next Year48.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-91.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-120.52%
OCF growth 3YN/A
OCF growth 5YN/A